Latest Funding News

Papyrus Australia has marked significant progress in July 2025 with successful testing at its Rapid Prototyping facility and advancing plans for a commercial production site, while also writing down key investments.

Elanor Investors Group reported a substantial $157.8 million net loss for FY24 amid asset devaluations and debt covenant breaches, prompting a strategic recapitalisation and leadership transition.

Acorn Capital Investment Fund Limited reported a robust FY25 with a $9.67 million profit after tax, a significant leap from $1.77 million the prior year, while delivering a 15.1% portfolio return that outperformed its benchmark.

Papyrus Australia reported a July 2025 cash flow update showing a stable cash position of AUD 303,000 and available funding supporting operations for over eight months. The company continues to manage its financing facilities prudently while navigating operational expenses.

Finexia Financial Group reported a significant net loss of $3.13 million for FY25, even as revenue jumped 59% to $23.8 million. The company also restated prior year results following accounting corrections.

Bougainville Copper Limited posted a deeper half-year loss as it ramps up exploration and navigates ongoing legal disputes tied to its historic Panguna mine. The company also advances infrastructure remediation under a key government agreement.

AssetOwl Limited reports a modest net profit for FY2025, driven by a significant gain on debt extinguishment, while grappling with ASX suspension and ongoing going concern challenges.

Althea Group Holdings reports a significant reduction in losses for FY25, driven by asset sales and strategic refocus on North American THC beverages. The company completed a $4 million capital raise and navigated leadership changes amid subsidiary liquidations.

Uscom Limited reported a 25% decline in revenue to $3.16 million and a 59% increase in net loss to $3.3 million for FY25, reflecting significant global headwinds. Despite setbacks, the company advanced new product approvals and secured funding to navigate ongoing challenges.

Seafarms Group Limited reported a reduced loss of $11.7 million for FY2025, despite a 43% drop in revenue and ongoing legal challenges surrounding Project Sea Dragon. Production setbacks from flooding and subdued market demand weighed heavily on results.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Spectur Limited reported a 6% revenue increase to $8.7 million and slashed its net loss by 70% to $779,000 in FY25, driven by operational restructuring and a shift toward recurring revenue streams.